Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries

10+ emerging markets, Japan & ANZ transition in final phase

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK

GSK registers 5% revenue growth in Q2 FY24

General Medicine grows 5% and Vaccines 10% led by Shingrix

CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData

CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology

Takara Bio Europe launches high-quality enzymes suitable for pre-clinical mRNA vaccine

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Ecolab expands biologics resin manufacturing facility in Pennsylvania

New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.

Lonza launches TheraPEAK T-VIVO cell culture medium to accelerate cell therapy development

Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing

H2 2022 sees 10 billion drop in total forecast sales of COVID-19 vaccines between 2021 and 2028, says GlobalData

The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028

Pharma companies developing vaccines with efficacy against Omicron variants will gain competitive advantage in China, says GlobalData

The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.